E Solsona

Summary

Country: Spain

Publications

  1. ncbi request reprint Late oncological occurrences following radical cystectomy in patients with bladder cancer
    E Solsona
    Department of Urology, Instituto Valenciano de Oncologi a, C Prof Beltrán Báguena 8, 46009, Valencia, Spain
    Eur Urol 43:489-94. 2003
  2. ncbi request reprint Best approach for low-risk superficial bladder cancer
    Eduardo Solsona
    Service of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    ScientificWorldJournal 6:2638-45. 2006
  3. doi request reprint Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer
    Eduardo Solsona
    Service of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    J Urol 184:475-80. 2010
  4. ncbi request reprint [Radical prostatectomy after radiotherapy]
    Eduardo Solsona
    Servicio de Urologia, Instituto Valenciano de Oncologia, Espana
    Arch Esp Urol 65:84-92. 2012
  5. ncbi request reprint New developments in the treatment of localized penile cancer
    Eduardo Solsona
    Servicio de Urologia, Instituto Valenciano de Oncologia, C Beltran Baguena 8, Valencia, Spain
    Urology 76:S36-42. 2010
  6. ncbi request reprint Risk groups in patients with bladder cancer treated with radical cystectomy: statistical and clinical model improving homogeneity
    E Solsona
    Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    J Urol 174:1226-30. 2005
  7. ncbi request reprint Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy
    Eduardo Solsona
    Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    Eur Urol 55:911-9. 2009
  8. ncbi request reprint The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour
    Eduardo Solsona
    Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    BJU Int 94:1258-62. 2004
  9. ncbi request reprint EAU Guidelines on Penile Cancer
    E Solsona
    Department of Urology, Fundació Instituto Valenciano de Oncologia, C P Beltran Baguena, 8 y 19, E 46009 Valencia, Spain
    Eur Urol 46:1-8. 2004
  10. ncbi request reprint [Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy]
    J Rubio-Briones
    Instituto Valenciano de Oncologia, Espana
    Actas Urol Esp 34:610-7. 2010

Collaborators

  • Per Uno Malmstrom
  • J Rubio-Briones
  • A Collado
  • M A Climent
  • David Ramos Soler
  • Amit Bahl
  • M Á Bonillo
  • G Pizzocaro
  • S Horenblas
  • P J Goebell
  • Jesus Fernandez-Gomez
  • J Morote
  • Andriy O Yurakh
  • W Oosterlinck
  • Hendrik VAN Poppel
  • H Akaza
  • I Iborra
  • J M Cozar
  • A Gómez-Ferrer
  • J Rubio
  • J V Ricos
  • J Casanova
  • J A Lopez-Guerrero
  • D Ramos
  • M Ramírez-Backhaus
  • José A Martínez-Piñeiro
  • J L Monros
  • A Fernández-Serra
  • Antonio Ojea
  • A Llombart-Bosch
  • S Almenar
  • Jesús María Fernández Gómez
  • Rosario Madero
  • Rafael Hernandez Rodríguez
  • Santiago Isorna
  • Jose Emilio Camacho
  • Jesús Rodríguez Molina
  • Nicolas Flores
  • J A Martinez-Pineiro
  • J Dominguez
  • A Gonzalez Del Alba
  • D Castellano
  • J Carles
  • A Alcaraz
  • B Minana
  • J P Maroto
  • M Trassierra
  • M P Rodriguez
  • A Huerta
  • J M Molero
  • F Leon
  • J F Perez
  • Z Garcia-Casado
  • I Pérez-Escolano
  • A Fernández-Pro
  • F Brenes
  • M Abba
  • C M Aldaz
  • Luís Martínez Piñeiro
  • Venancio Chantada
  • José Luís Nogueira
  • Miguel Blas
  • Luis Martinez-Pineiro
  • Salvador Arribas
  • Mariano Rabadan
  • Ander Astobieta
  • Marcelino González Martín
  • Carlos Pertusa
  • I Pereira
  • J Carballido
  • R Madero
  • J L Sebastian
  • J E Camacho
  • L Martinez-Pineiro
  • R Vela
  • N Chesa
  • S Isorna
  • F Galvis
  • C Pertusa
  • C Bernuy
  • J L Nogueira
  • L Resel
  • S Arribas
  • L A Rioja
  • N Flores
  • J A De Torres
  • P Muntanola

Detail Information

Publications29

  1. ncbi request reprint Late oncological occurrences following radical cystectomy in patients with bladder cancer
    E Solsona
    Department of Urology, Instituto Valenciano de Oncologi a, C Prof Beltrán Báguena 8, 46009, Valencia, Spain
    Eur Urol 43:489-94. 2003
    ..To evaluate the prognoses and predictive factors of late oncological occurrences and its impact on follow-up strategy in patients with bladder tumours treated with radical cystectomy...
  2. ncbi request reprint Best approach for low-risk superficial bladder cancer
    Eduardo Solsona
    Service of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    ScientificWorldJournal 6:2638-45. 2006
    ..This group has high recurrence and low progression rates. The standard treatment is the complete resection and postoperative single immediate instillation of whatever chemotherapy agent should be considered...
  3. doi request reprint Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer
    Eduardo Solsona
    Service of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    J Urol 184:475-80. 2010
    ..A followup schedule was developed based on progression and recurrence during this period...
  4. ncbi request reprint [Radical prostatectomy after radiotherapy]
    Eduardo Solsona
    Servicio de Urologia, Instituto Valenciano de Oncologia, Espana
    Arch Esp Urol 65:84-92. 2012
    ..In summary radical prostatectomy is a feasible rescue procedure after radiotherapy failure although the complications rate remains higher than prostatectomy as initial therapy...
  5. ncbi request reprint New developments in the treatment of localized penile cancer
    Eduardo Solsona
    Servicio de Urologia, Instituto Valenciano de Oncologia, C Beltran Baguena 8, Valencia, Spain
    Urology 76:S36-42. 2010
    ..To analyze the current trends in local therapy approaches in patients with penile carcinoma...
  6. ncbi request reprint Risk groups in patients with bladder cancer treated with radical cystectomy: statistical and clinical model improving homogeneity
    E Solsona
    Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    J Urol 174:1226-30. 2005
    ..In this study we identified homogeneous risk groups, with no survival overlap among the subgroups that make up each risk group, in patients with transitional cell carcinoma of the bladder treated with radical cystectomy alone...
  7. ncbi request reprint Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy
    Eduardo Solsona
    Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    Eur Urol 55:911-9. 2009
    ..Many phase 2 bladder-sparing programmes using transurethral resection of the bladder (TURB) plus chemotherapy or radio-chemotherapy have been undertaken, but some controversies remain...
  8. ncbi request reprint The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour
    Eduardo Solsona
    Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    BJU Int 94:1258-62. 2004
    ..To establish the optimum time of radical cystectomy (RC) for patients with recurrent high-risk superficial bladder tumours after the failure of intravesical therapy...
  9. ncbi request reprint EAU Guidelines on Penile Cancer
    E Solsona
    Department of Urology, Fundació Instituto Valenciano de Oncologia, C P Beltran Baguena, 8 y 19, E 46009 Valencia, Spain
    Eur Urol 46:1-8. 2004
    ....
  10. ncbi request reprint [Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy]
    J Rubio-Briones
    Instituto Valenciano de Oncologia, Espana
    Actas Urol Esp 34:610-7. 2010
    ..To determine our results in high risk (HR) prostate cancer (PCa) patients treated with radical prostatectomy (RP) and to establish preoperative prognosis factors...
  11. ncbi request reprint Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications
    E Solsona
    Departments of Urology and Pathology, Instituto Valenciano de Oncologia, Valencia, Spain
    J Urol 167:2007-11. 2002
    ..We established the prognostic and therapeutic implications of panurothelial involvement in patients with superficial bladder tumors for optimizing therapeutic approaches in those at risk for panurothelial involvement...
  12. doi request reprint [Reconstruction of the glans with free-skin graft applying the Bracka technique]
    A Gómez-Ferrer
    Servicio de Urologia, Instituto Valenciano de Oncologia, Valencia, Espana
    Actas Urol Esp 35:180-3. 2011
    ..We analyse our experience in the conservative surgical management of penile cancer and/or penile skin pathologies at our institution...
  13. doi request reprint [Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer]
    J Rubio-Briones
    Servicio de Urologia, Instituto Valenciano de Oncologia, Valencia, Espana
    Actas Urol Esp 35:589-96. 2011
    ..The aim of this study is to evaluate our outcomes in its routine use and to establish in which group of patients this is the most efficient, depending on the number of previous PCA3 biopsies...
  14. pmc Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours
    D Ramos
    Department of Pathology, School of Medicine, University of Valencia, Valencia, Spain
    Histopathology 52:831-9. 2008
    ..To correlate the immunohistochemical detection of WWOX with histological measures and disease progression within the whole spectrum of urothelial bladder neoplasms...
  15. ncbi request reprint Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens
    J Rubio
    Urology Service, Instituto Valenciano de Oncología IVO, C Prof Beltrán Báguena 8, 46009, Valencia, Spain
    Eur Urol 48:745-51. 2005
    ..To elucidate the prognostic value of the immunohistochemical (IHC) expression of Bcl-2, Bax, Cox-2 and Ki-67 antigen in biopsy cores (C) and surgical specimens (SP) of prostate cancer (PC) and to determine the C to SP reproducibility...
  16. ncbi request reprint Radical prostatectomy is a reasonable treatment for patients over 70 years of age
    M Ramírez-Backhaus
    Servicio de Urologia, Fundacion Instituto Valenciano de Oncologia, Valencia, España Electronic address
    Actas Urol Esp 38:21-7. 2014
    ..To compare the tumor nature and oncological course of patients operated on by radical prostatectomy in three age groups...
  17. ncbi request reprint Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program
    J Rubio-Briones
    Servicio de Urologia, Fundacion Instituto Valenciano de Oncologia, Valencia, España Electronic address
    Actas Urol Esp 38:217-23. 2014
    ..To reduce unnecessary biopsies (Bx) in an opportunistic screening programme of prostate cancer...
  18. doi request reprint [Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression]
    J Rubio-Briones
    Servicio de Urologia, Instituto Valenciano de Oncologia, Valencia, Espana
    Actas Urol Esp 35:80-6. 2011
    ..to correlate the immunohistochemical expression of microvascular density (MVD) and the carbonic anhydrase IX (CAIX) with the different histological subtypes of renal carcinoma and its progression...
  19. ncbi request reprint Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression
    I Iborra
    Department of Urology and Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain
    J Urol 169:82-5. 2003
    ..We evaluate the safety and efficacy of conservative elective treatment of upper urinary tract tumors, and determine predictive factors for recurrence and progression to optimize indications of this type of treatment...
  20. doi request reprint [Prostate cancer: the revolution of the fusion genes]
    A Fernández-Serra
    Laboratorio de Biologia Molecular, Fundacion Instituto Valenciano de Oncologia, Valencia, Espana
    Actas Urol Esp 35:420-8. 2011
    ..These genetic alterations lead the overexpression of ETS genes which encode the E26 family of transcription factors involved in cell proliferation. Of this family, the ERG oncogene is overexpressed in almost 50% of prostate cancer cases...
  21. ncbi request reprint Prospective validation of the association of local tumor stage and grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes
    E Solsona
    Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain
    J Urol 165:1506-9. 2001
    ..However, other prognostic factors are needed in the intermediate risk group to improve the prediction of lymph node involvement...
  22. ncbi request reprint Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer
    J A Martinez-Pineiro
    Hospital La Paz, Avenida San Luis 95, 28033 Madrid, Spain
    BJU Int 89:671-80. 2002
    ....
  23. doi request reprint [Recomendations on the management of controversies in advanced castrate-resistant prostate cancer]
    J M Cozar
    Servicio de Urologia, Hospital Universitario Virgen de las Nieves, Granada, Espana
    Actas Urol Esp 36:569-77. 2012
    ..Controversies and uncertainties among integral management of advanced castration resistant prostate cancer continue to exist despite the number of evidence based clinical practice guidelines published with high international consensus...
  24. doi request reprint [Clinical management of patient with benign prostatic hyperplasia in Spain]
    J M Cozar
    Servicio de Urologia, Hospital Universitario Virgen de las Nieves, Granada, Espana
    Actas Urol Esp 35:580-8. 2011
    ..To identify clinical management of benign prostatic hyperplasia (BPH) in Spain and its associated health care resources...
  25. ncbi request reprint A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomyci
    Antonio Ojea
    Complejo Hospitalario Universitario de Vigo, Vigo, Spain
    Eur Urol 52:1398-406. 2007
    ..The primary aim was to search for lower doses of Bacillus Calmette-Guerin (BCG) that are effective and have lower toxicity...
  26. ncbi request reprint Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder
    Andriy O Yurakh
    Institute of Urology, Academy of Medical Science of Ukraine, Kyiv, Ukraine
    Eur Urol 50:506-15; discussion 515. 2006
    ..To evaluate the prognostic and predictive value of molecular and immunohistochemical markers related to cell-cycle control in terms of recurrence, progression, and survival in urothelial neoplasms of the bladder (UNB)...
  27. ncbi request reprint Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial
    José A Martínez-Piñeiro
    La Luz Clinic, Madrid, Spain
    J Urol 174:1242-7. 2005
    ..Also, we evaluated toxic side effects...
  28. ncbi request reprint Low-grade Ta (noninvasive) urothelial carcinoma of the bladder
    Willem Oosterlinck
    Department of Urology, University Hospital Ghent, Ghent, Belgium
    Urology 66:75-89. 2005
    ..This should improve the quality of the treatment of this disease...
  29. ncbi request reprint Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials
    Jesus Fernandez-Gomez
    Department of Urology, Hospital Central of Asturias, University of Oviedo, Oviedo, Spain
    Eur Urol 53:992-1001. 2008
    ..To evaluate the prognostic factors of recurrence and progression after intravesical adjuvant bacillus Calmette-Guérin (BCG) immunotherapy in patients with non-muscle-invasive bladder tumors...